| Abstract | OBJECTIVES: Akathisia is a clinical important symptom, frequently induced by neuroleptic treatment. Despite its clinical importance, less is known about its pathophysiology. METHODS: Using [18]-FDG-PET, imaging patterns of cortical metabolic activity were obtained in a patient during olanzapine-induced akathisia and after recovery. RESULTS: Akathisia was characterized by a reduced metabolic activity in thalamus and cerebellum. After discontinuing medication akathisia disappeared, reflected by a recovery of metabolic activity in these brain areas. CONCLUSION: [18]-FDG-PET may be useful to identify cortical regions mediating clinical aspects of drug-induced akathisia, thereby offering a deeper insight into the pathophysiology of this serious side effect. |
| Authors | Michael Landgrebe, Jörg Marienhagen, Berthold Langguth, Philipp Sand, Peter Eichhammer, Göran Hajak
(Affiliation: Department of Psychiatry, Psychosomatics and Psychotherapy, University of Regensburg, Germany.)
|
| Journal | Neuro endocrinology letters
(Neuro Endocrinol Lett)
Vol. 27
Issue 6
Pg. 737-9
(Dec 2006)
ISSN: 0172-780X Sweden |
| PMID | 17187000
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Antipsychotic Agents
- Benzodiazepines
- Radiopharmaceuticals
- olanzapine
- Fluorodeoxyglucose F18
|
| Topics |
- Acute Disease
- Akathisia, Drug-Induced
(metabolism, radionuclide imaging)
- Antipsychotic Agents
(adverse effects, therapeutic use)
- Benzodiazepines
(adverse effects, therapeutic use)
- Cerebellum
(drug effects, metabolism, radionuclide imaging)
- Fluorodeoxyglucose F18
(diagnostic use)
- Humans
- Male
- Middle Aged
- Positron-Emission Tomography
(methods)
- Radiopharmaceuticals
(diagnostic use)
- Schizophrenia
(complications, drug therapy, radionuclide imaging)
- Thalamus
(drug effects, metabolism, radionuclide imaging)
|
